Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial

BACKGROUND: Well-differentiated (WD) neuroendocrine tumors (NETs) are a group of rare neoplasms with limited therapeutic options. Cabozantinib is an inhibitor of multiple tyrosine kinases with a pivotal role in NET pathogenesis, including c-MET and Vascular Endothelial Growth Factor Receptor 2 (VEGF...

Descripción completa

Detalles Bibliográficos
Autores principales: Corti, Francesca, Brizzi, Maria Pia, Amoroso, Vito, Giuffrida, Dario, Panzuto, Francesco, Campana, Davide, Prinzi, Natalie, Milione, Massimo, Cascella, Tommaso, Spreafico, Carlo, Randon, Giovanni, Oldani, Simone, Leporati, Rita, Scotto, Giulia, Pulice, Iolanda, Stocchetti, Benedetta Lombardi, Porcu, Luca, Coppa, Jorgelina, Di Bartolomeo, Maria, de Braud, Filippo, Pusceddu, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523723/
https://www.ncbi.nlm.nih.gov/pubmed/37752423
http://dx.doi.org/10.1186/s12885-023-11287-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523723/
https://www.ncbi.nlm.nih.gov/pubmed/37752423
http://dx.doi.org/10.1186/s12885-023-11287-2

Ejemplares similares